Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SONN 
Sonnet Biotherapeutics Holdings Inc (SONN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: SONN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.92% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.97M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta 0.94 | 52 Weeks Range 1.08 - 8.72 | Updated Date 07/8/2025 |
52 Weeks Range 1.08 - 8.72 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1378.09% |
Management Effectiveness
Return on Assets (TTM) -176.75% | Return on Equity (TTM) -714.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13005443 | Price to Sales(TTM) 14.97 |
Enterprise Value 13005443 | Price to Sales(TTM) 14.97 | ||
Enterprise Value to Revenue 13.01 | Enterprise Value to EBITDA -0.21 | Shares Outstanding 3165810 | Shares Floating 3133076 |
Shares Outstanding 3165810 | Shares Floating 3133076 | ||
Percent Insiders 1.53 | Percent Institutions 5.24 |
Upturn AI SWOT
Sonnet Biotherapeutics Holdings Inc
Company Overview
History and Background
Sonnet Biotherapeutics Holdings Inc. is a biotechnology company focused on developing innovative therapies for oncology and other diseases. Founded to leverage its Fully Human Albumin Binding (FHAB) technology, the company aims to improve drug delivery and efficacy. While precise founding year and detailed milestones were unavailable, its evolution is marked by preclinical and clinical programs focused on targeted drug delivery.
Core Business Areas
- Oncology Therapeutics: Development of immunotherapeutic and targeted therapies for various cancers, leveraging their FHAB technology platform.
- FHAB Technology Platform: Licensing and development of therapeutic candidates based on its Fully Human Albumin Binding (FHAB) technology platform, enhancing drug bioavailability and tumor targeting.
Leadership and Structure
The leadership team consists of experienced professionals in biotechnology, including a CEO, CSO, and CFO. Organizational structure is typical of a clinical-stage biotech company, with departments for research and development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- SON-1010 (IL-12-FHAB): A clinical-stage candidate utilizing FHAB technology to deliver IL-12 to the tumor microenvironment. Currently in clinical trials for various cancers. Market share data is unavailable as it is pre-commercialization. Competitors include companies developing IL-12 therapies and other cancer immunotherapies like Merck (KEYTRUDA) and Bristol Myers Squibb (OPDIVO).
- SON-080 (IL-6-FHAB): Another clinical-stage candidate utilizing FHAB to deliver IL-6 to the tumor microenvironment for hematopoiesis. Competitors include companies developing treatments for chemotherapy induced hematopoiesis.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high innovation, long development timelines, and significant regulatory hurdles. Oncology is a major area of focus, with increasing demand for targeted therapies and immunotherapies.
Positioning
Sonnet Biotherapeutics positions itself as an innovator in targeted drug delivery using its FHAB technology, aiming to improve efficacy and reduce toxicity of cancer therapies. Their competitive advantage lies in the FHAB platform's potential to enhance drug bioavailability and tumor targeting.
Total Addressable Market (TAM)
The total addressable market for cancer therapeutics is estimated to be hundreds of billions of dollars. Sonnet is positioned to capture a portion of this TAM through successful development and commercialization of its FHAB-based therapies, focusing on niche areas like IL-12 and IL-6 targeted delivery. TAM is dependent on specific indications and success of clinical trials.
Upturn SWOT Analysis
Strengths
- Proprietary FHAB technology platform
- Clinical-stage therapeutic candidates
- Experienced leadership team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- No currently approved products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results leading to accelerated approval
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Difficulty raising capital
Competitors and Market Share
Key Competitors
- MRK
- BMY
- NVO
Competitive Landscape
Sonnet Biotherapeutics faces intense competition from established pharmaceutical companies with greater resources. Its FHAB technology offers a potential competitive advantage if clinical trials demonstrate superior efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by research and development progress rather than revenue generation.
Future Projections: Future growth is contingent on successful clinical trials and potential partnerships. Analyst estimates are dependent on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials for SON-1010 and SON-080, securing funding through equity offerings, and exploring potential partnerships.
Summary
Sonnet Biotherapeutics is a clinical-stage company with a promising FHAB technology platform. It has the potential to improve targeted drug delivery and efficacy. However, it faces significant challenges including limited financial resources, clinical trial risks, and competition from larger pharmaceutical companies. Positive clinical trial outcomes and strategic partnerships are crucial for its success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Yahoo Finance
- Seeking Alpha
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on available information and estimates, and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sonnet Biotherapeutics Holdings Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2006-10-31 | Interim CEO & Director Mr. Raghu Rao | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.sonnetbio.com |
Full time employees 13 | Website https://www.sonnetbio.com | ||
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.